



## THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of Lenhard et al.

Serial No.: 09/441,493

Group Art Unit: 3736

Filed: November 17, 1999

Examiner: R. Zeman

For: *Infrared Thermography*Commissioner for Patents  
Washington, D.C. 20231

TECHNOLOGY CENTER R3700

JUN 11 2001

RECEIVED

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed  
☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_. (37 CFR 1.98(d))  
☒ A copy of the International Search Report which issued on International Application No. PCT/US00/31755 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449.

- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311,

whichever occurs first.

RECEIVED

JUN 14 2001

TECH CENTER 1600/2900

- ☒ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge required fees to Deposit Account No.07-1392.

☒ A duplicate copy of this paper is attached.



23347

PATENT, TRADEMARK OFFICE

GlaxoSmithKline  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Telephone: (919) 483-2482  
Facsimile: (919) 483-7977

Respectfully Submitted,

Frank P. Grassler

Registration No. 31,164

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on June 4, 2001 in accordance with the provisions of 37 CFR § 1.8.

  
Marjorie J. Pfeiffer